Clinical trials are underway to determine if a reduction in serum apelin levels can be used to assess the efficacy of bevacizumab treatment as a measure of tumor vasculature normalization following similar observations in a mouse model (Zhang et al., 2016). This evidence concerns the gene APLN and neoplasm.